MELA Sciences Inc  

(Public, NASDAQ:MELA)   Watch this stock  
Find more results for MELA
0.818
-0.010 (-1.20%)
Real-time:   3:48PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.81 - 0.84
52 week 0.81 - 4.37
Open 0.84
Vol / Avg. 313,205.00/533,938.00
Mkt cap 35.23M
P/E     -
Div/yield     -
EPS -0.71
Shares 43.04M
Beta 0.78
Inst. own 26%
Aug 5, 2013
Q2 2013 MELA Sciences Earnings Release Add to calendar
May 6, 2013
MELA Sciences Analyst Meeting - Webcast
May 1, 2013
MELA Sciences at Needham Healthcare Conference - Webcast
Apr 30, 2013
Q1 2013 MELA Sciences Earnings Conference Call - Webcast
Apr 29, 2013
Q1 2013 MELA Sciences Earnings Release
Apr 25, 2013
MELA Sciences Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -4518.82% -8142.11%
Operating margin -4500.62% -8160.80%
EBITD margin - -7812.82%
Return on average assets -106.38% -93.18%
Return on average equity -139.64% -103.57%
Employees 71 -
Carbon Disclosure Rating - -

Address

Suite 1, 50 South Buckhout St.
IRVINGTON, NY 10533
United States - Map
+1-914-5913783 (Phone)
+1-914-5913785 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

MELA Sciences, Inc. is a medical device company focused on the commercialization of its product, MelaFind, and the further design and development of MelaFind and its technology. MelaFind is a non-invasive, point-of-care (in the doctor's office) instrument to aid in the detection of melanoma. MelaFind, features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing classification algorithms, trained on the Company's database of melanomas and benign lesions, to provide information to assist in the management of the patient's disease, including information useful in the decision whether to biopsy the lesion.

Officers and directors

Joseph V. Gulfo M.D. Chairman of the Board, President, Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Richard I. Steinhart Chief Financial Officer, Vice President - Finance, Treasurer, Secretary
Bio & Compensation  - Reuters
Nikolai Kabelev Vice President - Research & Development
Age: 35
Bio & Compensation  - Reuters
David K Stone Lead Independent Director
Age: 55
Bio & Compensation  - Reuters
Robert Coradini Independent Director
Age: 52
Bio & Compensation  - Reuters
Anne Egger Independent Director
Age: 59
Bio & Compensation  - Reuters
Mark Fabiani Independent Director
Age: 54
Bio & Compensation  - Reuters
John Geoffery Goddard Independent Director
Age: 60
Bio & Compensation  - Reuters